Skip to main content

Ataxia-Telangiectasia

OMIM ID:

autosomal recessive

Ataxia-Telangiectasia

Alternate Names

Louis-Bar syndrome
AT1

Defective Genes

ATM

Clinical Characteristics

Ocular Features

The ocular manifestations are striking although of little clinical consequence.  The conjunctivae have prominent telangiectases which usually develop between 3 and 5 years of age.  These apparently do not occur intraocularly.    Oculomotor apraxia is often an earlier sign consisting of difficulty in initiation of smooth pursuit movements which patients may modify by head motion in the direction of attempted gaze.  This aspect can be helpful in diagnosis of AT in young children with cerebellar ataxia. 

Systemic Features

Telangiectases are often found in the pinnae, on the cheeks, and on the forearms, usually after the onset of neurological signs.  However, this is also a disorder with multiple systemic signs, the most serious of which are unusual sensitivity to ionizing radiation, excessive chromosomal breakage, a deficiency in the immune system, mild cognitive impairment, and increased risk of malignancies.  Lymphomas, often of B-cell origin, and leukemia, usually of T-cell origin, are the most common malignancies but there is a significantly increased risk of breast cancer as well. Serum IgG2 and IgA levels are often reduced and sinopulmonary infections are common.  Serum alpha-fetoprotein levels are usually increased.  The ataxia is progressive and often begins as truncal unsteadiness with limbs involved later.  It is often accompanied by choreoathetosis and/or dystonia which may result in severe disability by the second decade.  Life span is shortened and many patients succumb to their disease by the 3rd and 4th decades. 

In some famiies with confirmed mutations in ATM the disorder presents with signs of primary torsion dystonia and myoclonus-dystonia.  These signs may resemble an apparent autosomal dominant pattern with parent-child transmission.  It is unclear whether these families represent a variant of AT or a unique disorder.  The latter is suggested by an earlier onset of signs, the lack of cerebellar atrophy,  and the absence of ataxia and ocular telangiectases on initial presentation.  The risk of malignancies in these famiies is high.

Some of these signs have been reported in milder form among heterozygous carriers as well.  The most serious is an increased risk of malignancy, perhaps as much as 6.1 times that of non-carriers.  This combined with the inherent sensitivity to ionizing radiation has led to the suggestion that X-rays should be used with caution, especially when considering mammograms among female relatives.

 

Genetics

Inheritance

This is an autosomal recessive disorder as a result of mutations in the ATM gene located at 11q22-q23.  Affected offspring of consanguineous matings are often homozygous for this mutation whereas those from unrelated parents are usually compound heterozygotes.  There is some evidence of genetic heterogeneity based on both clinical and DNA studies (AT variants).

Other conditions with oculomotor apraxia are: ataxia with oculomotor apraxia 1 (208920), ataxia with oculomotor apraxia 2 (602600), and Cogan type oculomotor apraxia (257550) which lacks other neurologic signs. Oculomotor apraxia may be the presenting sign in Gaucher disease (230800, 230900, 231000).

Pedigree

Autosomal recessive

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent.  Carriers with only one mutation, such as the parents, do not have clinical disease.  Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Image
Sample pedigree of autosomal recessive inheritance

In order for autosomal recessive disorders to be expressed, offspring generally must inherit two mutations, one from each carrier parent. Carriers with only one mutation, such as the parents, do not have clinical disease. Note that carrier parents can expect that 1 in 4 children (25%) will inherit both mutations and have the disorder, 2 in 4 children (50%) will be carriers like their parents, while 1 in 4 children (25%) inherit neither mutation.

Treatment & Management

No treatment is known for the neurologic manifestations.  However, patients and first degree relatives should be monitored for malignancies.  Childhood vaccinations may lead to widespread viral dissemination as a consequence of the immune defect.

Selected Resources

Publications

Displaying 1 - 5 of 5

Ataxia telangiectasia: a review

PubMedID: 27884168

Ataxia-telangiectasia: an interdisciplinary approach to pathogenesis

PubMedID: 2005780

Breast and Other Cancers in Families with Ataxia-Telangiectasia

PubMedID: 3574400

Cognitive Phenotype in Ataxia-Telangiectasia

PubMedID: 25037873

Variant ataxia-telangiectasia presenting as primary-appearing dystonia in Canadian Mennonites

PubMedID: 22345219